ScinoPharm Taiwan Ltd
TWSE:1789

Watchlist Manager
ScinoPharm Taiwan Ltd Logo
ScinoPharm Taiwan Ltd
TWSE:1789
Watchlist
Price: 23.5 TWD -0.63% Market Closed
Market Cap: 18.6B TWD
Have any thoughts about
ScinoPharm Taiwan Ltd?
Write Note

Intrinsic Value

The intrinsic value of one ScinoPharm Taiwan Ltd stock under the Base Case scenario is 16.52 TWD. Compared to the current market price of 23.5 TWD, ScinoPharm Taiwan Ltd is Overvalued by 30%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
16.52 TWD
Overvaluation 30%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
ScinoPharm Taiwan Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ScinoPharm Taiwan Ltd cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ScinoPharm Taiwan Ltd?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about ScinoPharm Taiwan Ltd

Provide an overview of the primary business activities
of ScinoPharm Taiwan Ltd.

What unique competitive advantages
does ScinoPharm Taiwan Ltd hold over its rivals?

What risks and challenges
does ScinoPharm Taiwan Ltd face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for ScinoPharm Taiwan Ltd.

Provide P/S
for ScinoPharm Taiwan Ltd.

Provide P/E
for ScinoPharm Taiwan Ltd.

Provide P/OCF
for ScinoPharm Taiwan Ltd.

Provide P/FCFE
for ScinoPharm Taiwan Ltd.

Provide P/B
for ScinoPharm Taiwan Ltd.

Provide EV/S
for ScinoPharm Taiwan Ltd.

Provide EV/GP
for ScinoPharm Taiwan Ltd.

Provide EV/EBITDA
for ScinoPharm Taiwan Ltd.

Provide EV/EBIT
for ScinoPharm Taiwan Ltd.

Provide EV/OCF
for ScinoPharm Taiwan Ltd.

Provide EV/FCFF
for ScinoPharm Taiwan Ltd.

Provide EV/IC
for ScinoPharm Taiwan Ltd.

Show me price targets
for ScinoPharm Taiwan Ltd made by professional analysts.

What are the Revenue projections
for ScinoPharm Taiwan Ltd?

How accurate were the past Revenue estimates
for ScinoPharm Taiwan Ltd?

What are the Net Income projections
for ScinoPharm Taiwan Ltd?

How accurate were the past Net Income estimates
for ScinoPharm Taiwan Ltd?

What are the EPS projections
for ScinoPharm Taiwan Ltd?

How accurate were the past EPS estimates
for ScinoPharm Taiwan Ltd?

What are the EBIT projections
for ScinoPharm Taiwan Ltd?

How accurate were the past EBIT estimates
for ScinoPharm Taiwan Ltd?

Compare the revenue forecasts
for ScinoPharm Taiwan Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of ScinoPharm Taiwan Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of ScinoPharm Taiwan Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of ScinoPharm Taiwan Ltd compared to its peers.

Compare the P/E ratios
of ScinoPharm Taiwan Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing ScinoPharm Taiwan Ltd with its peers.

Analyze the financial leverage
of ScinoPharm Taiwan Ltd compared to its main competitors.

Show all profitability ratios
for ScinoPharm Taiwan Ltd.

Provide ROE
for ScinoPharm Taiwan Ltd.

Provide ROA
for ScinoPharm Taiwan Ltd.

Provide ROIC
for ScinoPharm Taiwan Ltd.

Provide ROCE
for ScinoPharm Taiwan Ltd.

Provide Gross Margin
for ScinoPharm Taiwan Ltd.

Provide Operating Margin
for ScinoPharm Taiwan Ltd.

Provide Net Margin
for ScinoPharm Taiwan Ltd.

Provide FCF Margin
for ScinoPharm Taiwan Ltd.

Show all solvency ratios
for ScinoPharm Taiwan Ltd.

Provide D/E Ratio
for ScinoPharm Taiwan Ltd.

Provide D/A Ratio
for ScinoPharm Taiwan Ltd.

Provide Interest Coverage Ratio
for ScinoPharm Taiwan Ltd.

Provide Altman Z-Score Ratio
for ScinoPharm Taiwan Ltd.

Provide Quick Ratio
for ScinoPharm Taiwan Ltd.

Provide Current Ratio
for ScinoPharm Taiwan Ltd.

Provide Cash Ratio
for ScinoPharm Taiwan Ltd.

What is the historical Revenue growth
over the last 5 years for ScinoPharm Taiwan Ltd?

What is the historical Net Income growth
over the last 5 years for ScinoPharm Taiwan Ltd?

What is the current Free Cash Flow
of ScinoPharm Taiwan Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for ScinoPharm Taiwan Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
ScinoPharm Taiwan Ltd

Current Assets 6.7B
Cash & Short-Term Investments 4.2B
Receivables 494.2m
Other Current Assets 2B
Non-Current Assets 5.3B
Long-Term Investments 80.3m
PP&E 4.6B
Intangibles 18.3m
Other Non-Current Assets 634.9m
Current Liabilities 972.5m
Accounts Payable 149.4m
Accrued Liabilities 122.9m
Short-Term Debt 8.9m
Other Current Liabilities 691.4m
Non-Current Liabilities 651.2m
Long-Term Debt 624.9m
Other Non-Current Liabilities 26.2m
Efficiency

Earnings Waterfall
ScinoPharm Taiwan Ltd

Revenue
3.4B TWD
Cost of Revenue
-2.1B TWD
Gross Profit
1.3B TWD
Operating Expenses
-891.2m TWD
Operating Income
442.1m TWD
Other Expenses
-39.1m TWD
Net Income
403m TWD

Free Cash Flow Analysis
ScinoPharm Taiwan Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

Profitability Score
Profitability Due Diligence

ScinoPharm Taiwan Ltd's profitability score is 50/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Positive 3-Years Revenue Growth
Positive 1-Year Revenue Growth
50/100
Profitability
Score

ScinoPharm Taiwan Ltd's profitability score is 50/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

ScinoPharm Taiwan Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
99/100
Solvency
Score

ScinoPharm Taiwan Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
ScinoPharm Taiwan Ltd

There are no price targets for ScinoPharm Taiwan Ltd.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ScinoPharm Taiwan Ltd?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for ScinoPharm Taiwan Ltd is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

ScinoPharm Taiwan Ltd Logo
ScinoPharm Taiwan Ltd

Country

Taiwan

Industry

Pharmaceuticals

Market Cap

18.6B TWD

Dividend Yield

0%

Description

ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. The company is headquartered in Tainan, Tainan. The company went IPO on 2010-10-29. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The firm is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The firm operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.

Contact

TAINAN
Tainan
No.1, Nan-Ke 8th Road, Southern Taiwan Science Park, Shan-Hua District
+88665052888
www.scinopharm.com.tw

IPO

2010-10-29

Employees

-

Officers

Chairman & General Chief Strategy Officer
Mr. Chih-Hsien Lo
President & CEO
Ms. Li-An Lu
Acting Financial Off., Senior Director of Acct., Acct. Off., Acting Spokesperson & Corp. Gov. Off.
Ms. Chih-Hui Lin
Vice-President of Marketing, Sales & Operations
Mr. Ling-Hsiao Lien
VP of R&D Division and Chief Scientific Officer
Dr. Li-Chiao Chang Chemistry, Ph.D.
Director of Human Resources & Admin
Mr. Jason Chen
Show More
Director of Corporate Development
Mr. Shun Yang Lin
Show Less

See Also

Discover More
What is the Intrinsic Value of one ScinoPharm Taiwan Ltd stock?

The intrinsic value of one ScinoPharm Taiwan Ltd stock under the Base Case scenario is 16.52 TWD.

Is ScinoPharm Taiwan Ltd stock undervalued or overvalued?

Compared to the current market price of 23.5 TWD, ScinoPharm Taiwan Ltd is Overvalued by 30%.

Back to Top